INTRODUCTION: Phospholipid transfer protein (PLTP) is mainly involved in high-density lipoprotein (HDL) metabolism. The role of PLTP in atherogenesis is still controversial. We aimed to investigate PLTP activity in hemodialysis (HD) patients, a population which has an increased risk for the development of atherosclerosis. METHODS: PLTP activity and other markers were analyzed in blood samples from 68 HD patients and in a matched group of 68 healthy controls. RESULTS: Serum PLTP activity was nearly doubled in HD patients in comparison to healthy controls (median 43.0 vs. 22.4 pmol/mul/h, p < 0.001). In HD patients, PLTP activity correlated with HDL-C (r = 0.342, p = 0.004), but not with CRP (r = -0.057, p = 0.644) or leukocyte count (r = 0.116, p = 0.345). After a follow-up of 2 years, 26 HD patients had died. Kaplan-Meier analyses showed that low CRP (p = 0.047) but neither high HDL-C (p = 0.071) nor low PLTP activity (p = 0.853) were relevantly related to survival of HD patients. CONCLUSION: An elevated PLTP activity in HD patients may be considered as a further aspect of uremic dyslipidemia in HD patients. However, PLTP activity was not related to markers of inflammation or to survival of HD patients, even though it correlated with HDL-C. Thus, we conclude that PLTP does not influence the prognostically relevant inflammatory process in HD patients although it does influence the composition of HDL particles. Copyright 2007 S. Karger AG, Basel.
INTRODUCTION:Phospholipid transfer protein (PLTP) is mainly involved in high-density lipoprotein (HDL) metabolism. The role of PLTP in atherogenesis is still controversial. We aimed to investigate PLTP activity in hemodialysis (HD) patients, a population which has an increased risk for the development of atherosclerosis. METHODS:PLTP activity and other markers were analyzed in blood samples from 68 HDpatients and in a matched group of 68 healthy controls. RESULTS: Serum PLTP activity was nearly doubled in HDpatients in comparison to healthy controls (median 43.0 vs. 22.4 pmol/mul/h, p < 0.001). In HDpatients, PLTP activity correlated with HDL-C (r = 0.342, p = 0.004), but not with CRP (r = -0.057, p = 0.644) or leukocyte count (r = 0.116, p = 0.345). After a follow-up of 2 years, 26 HDpatients had died. Kaplan-Meier analyses showed that low CRP (p = 0.047) but neither high HDL-C (p = 0.071) nor low PLTP activity (p = 0.853) were relevantly related to survival of HDpatients. CONCLUSION: An elevated PLTP activity in HDpatients may be considered as a further aspect of uremic dyslipidemia in HDpatients. However, PLTP activity was not related to markers of inflammation or to survival of HDpatients, even though it correlated with HDL-C. Thus, we conclude that PLTP does not influence the prognostically relevant inflammatory process in HDpatients although it does influence the composition of HDL particles. Copyright 2007 S. Karger AG, Basel.
Authors: Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle Journal: Kidney Int Date: 2017-07-26 Impact factor: 10.612
Authors: Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche Journal: J Am Soc Nephrol Date: 2015-03-05 Impact factor: 10.121
Authors: Axel Schlitt; Stefan Blankenberg; Christoph Bickel; Karl J Lackner; Gunnar H Heine; Michael Buerke; Karl Werdan; Lars Maegdefessel; Uwe Raaz; Hans J Rupprecht; Thomas Munzel; Xian-Cheng Jiang Journal: J Lipid Res Date: 2008-11-10 Impact factor: 5.922
Authors: Axel Schlitt; Bernhard Schwaab; Kirsten Fingscheidt; Karl J Lackner; Gunnar H Heine; Alexander Vogt; Michael Buerke; Lars Maegdefessel; Uwe Raaz; Karl Werdan; Xian-Cheng Jiang Journal: Lipids Date: 2010-01-27 Impact factor: 1.880